2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2283 Time of day of BCMA CAR-T infusion and clinical outcomes in multiple myeloma

Jake Carrion, Matthew Ho, MBBS, PhD2, Ottavia Zattra, MD3, Luca Paruzzo, MD4, Heta Patel, MD5, Andrew A. Lin, MD, PhD6, Lukas Ronner, MD MSCR7, Yi Lian8, Janna Minehart, MD9, Alberto Carturan, MD10, Neel Ravi Nabar, MD, PhD11, Adam Waxman, MD, MS12, Shivani Kapur, MD13, Andrew Huff14, Fang Chen15, Joseph Fraietta, PhD16, Marco Ruella, MD17, Edward A. Stadtmauer, MD18, Dan T. Vogl, MD, MSCE19, Adam D. Cohen, MD20, Alfred L. Garfall, MD21, Sandra Susanibar-Adaniya, MD, MS22
1 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
19 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
20 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
21 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
22 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background: Although B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory multiple myeloma (MM), substantial interpatient variability persists in both treatment durability and toxicity, and the factors underlying this heterogeneity remain incompletely understood. Circadian rhythms regulate key immune processes implicated in CAR T-cell function, including lymphocyte trafficking, T-cell activation, monocyte function, cytokine production, and endothelial activation, suggesting that infusion timing may contribute to this variability. Prior studies of CD19-directed CAR T-cell therapy have associated earlier infusion times with improved clinical outcomes; however, evidence for BCMA-directed CAR T-cell therapy remains limited and inconclusive. We therefore evaluated the association between infusion timing and clinical outcomes following commercial BCMA-directed CAR T-cell therapy in patients with MM.

Methods: We retrospectively evaluated all adults with MM treated with commercial ciltacabtagene autoleucel (cilta-cel; n=208) or idecabtagene vicleucel (ide-cel; n=76) at the University of Pennsylvania between June 2021 and March 2026. The noon infusion cutoff was prespecified to match prior CD19 CAR T-cell chronotherapy studies; infusions before noon were classified as morning (AM) and those at or after noon as afternoon (PM). Prespecified endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), CAR T-cell-associated immune-related adverse events (CirAE), and peak absolute lymphocyte count (ALC) through Day 14. Given product-specific differences in efficacy, CirAE incidence, and CAR T-cell expansion kinetics, ide-cel and cilta-cel were analyzed separately. Cox proportional hazards and logistic regression models evaluated time-to-event and binary outcomes, respectively. Because only one ICANS event occurred among afternoon-infused patients, categorical ICANS analyses used Firth-penalized logistic regression. Sensitivity analysis modeled infusion time continuously as hours after 9:00 AM. Multivariable ICANS models adjusted for infusion date and clinically relevant pre-infusion ICANS risk factors, including age, ECOG performance status, disease burden, and baseline ferritin.

Results: Median infusion time was 11:22 AM, with AM and PM subgroup medians of 11:13 AM and 12:41 PM, respectively. Infusion period was not associated with efficacy, toxicity, or peak Day 14 ALC in the ide-cel cohort, nor with ORR, PFS, OS, CirAE, CRS, or peak Day 14 ALC among cilta-cel recipients. In contrast, morning infusion was associated with a higher incidence of ICANS (16.9% [26/154] vs 1.9% [1/54]; Firth OR, 7.4; 95% CI, 1.8–66.9), despite more frequent dexamethasone use before ICANS onset among AM recipients (27% vs 15%). The association remained robust after adjustment for infusion date and clinically relevant pre-infusion ICANS risk factors (adjusted OR, 7.4; 95% CI, 1.9–62.9). Continuous-time analyses yielded consistent findings, with each 1-hour later infusion associated with lower odds of ICANS (OR, 0.6; 95% CI, 0.3–0.9). In exploratory analyses of 27 cilta-cel recipients, Day 7 serum concentrations of IL-6, IL-15, and MCP-1, cytokines previously implicated in ICANS, were nominally higher after morning infusion, whereas IL-12(p40) was nominally higher after afternoon infusion. However, because Day 7 sampling did not uniformly precede ICANS onset and comparisons were not adjusted for multiple testing, these cytokine findings should be interpreted as correlative.

Conclusions: Overall, infusion timing was not associated with efficacy, CirAE, or CRS. Earlier cilta-cel infusion was, however, associated with a higher incidence of predominantly low-grade ICANS, although the observational design, sparse afternoon ICANS events, and narrow separation in infusion times preclude causal inference. Confirmation in larger, multicenter cohorts spanning a wider range of infusion times is needed to determine whether infusion timing represents a modifiable risk factor for ICANS.

Jake Carrion: No relevant conflicts of interest to declare.